Evidence map›Paper›PMID 22886976›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2012

Inhibitory effect of live-attenuated Listeria monocytogenes-based vaccines expressing MIA gene on malignant melanoma.

Yue Qian, Na Zhang, Ping Jiang, Siyuan Chen, Shujuan Chu, Firas Hamze, Yan Wu, Qin Luo, Aiping Feng

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. HarnessingArchives of Razi Institute · 2025
    Review
  2. Frontiers in immunology · 2023
    Review
  3. A Genetically Modified attenuatedFrontiers in cellular and infection microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yue QianDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China.
Na ZhangDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China.
Ping JiangDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China.
Siyuan ChenDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China.
Shujuan ChuDepartment of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Firas HamzeDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yan WuDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China.
Qin LuoCollege of Life Science, Huazhong Normal University, Wuhan, 430079, China.
Aiping FengDepartment of Dermatology, Huazhong University of Science and Technology, Wuhan, 430022, China. fengap195@yahoo.cn.
Huazhong University of Science and Technology · CNCentral China Normal University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Listeria monocytogenes (LM), a Gram-positive facultative intracellular bacterium, can be used as an effective exogenous antigen expression vector in tumor-target therapy. But for successful clinical application, it is necessary to construct attenuated LM stain that is safe yet retains the potency of LM based on the full virulent pathogen. In this study, attenuated LM and recombinants of LM expressing melanoma inhibitory activity (MIA) were constructed successfully. The median lethal dose (LD(50)) and invasion efficiency of attenuated LM strains were detected. The recombinants were utilized for immunotherapy of animal model of B16F10 melanoma. The level of MIA mRNA expression in tumor tissue was detected by using real-time polymerase chain reaction (PCR) with specific sequence, meanwhile the anti-tumor immune response was assayed by flow cytometric analysis and enzyme-linked immunosorbent spot (ELISPOT) assay. The results showed the toxicity and invasiveness of attenuated LM were decreased as compared with LM, and attenuated LM expressing MIA, especially the double-genes attenuated LM recombinant, could significantly induce anti-tumor immune response and inhibit tumor growth. This study implicates attenuated LM may be a safer and more effective vector for immunotherapy of melanoma.

Indexed as

AnimalsCancer VaccinesExtracellular Matrix ProteinsListeria monocytogenesMaleMelanomaMiceMice, Inbred C57BLVaccines, AttenuatedCancer VaccinesExtracellular Matrix ProteinsMia protein, mouseVaccines, Attenuated

Identifiers

PMID22886976
OpenAlexW70728035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.